Daihan Pharmaceutical Co.Ltd Cash Flow-to-Debt Ratio
Daihan Pharmaceutical Co.Ltd cash flow-to-debt ratio. Daihan Pharmaceutical Co.Ltd (023910) has a Cash Flow-to-Debt Ratio of 0.19x as of September 2025, meaning its operating cash flow of ₩9.47 Billion could theoretically repay 0% of its total liabilities (₩50.75 Billion) in one year. Check 023910 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Daihan Pharmaceutical Co.Ltd (2014–2024)
Cash flow-to-debt ratio of Daihan Pharmaceutical Co.Ltd from 2014 to 2024. Historical debt coverage capacity for Daihan Pharmaceutical Co.Ltd across 11 annual periods. Check Daihan Pharmaceutical Co.Ltd (023910) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Daihan Pharmaceutical Co.Ltd Cash Flow-to-Debt Ratio by Year (2014–2024)
Daihan Pharmaceutical Co.Ltd cash flow-to-debt ratio by year from 2014 to 2024. Year-by-year debt coverage analysis for Daihan Pharmaceutical Co.Ltd. For the full cash flow conversion analysis, see Daihan Pharmaceutical Co.Ltd (023910) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.74x | ₩35.64 Billion | ₩48.42 Billion | ▼ -12.3% |
| 2023 | 0.84x | ₩38.86 Billion | ₩46.28 Billion | ▲ +49.4% |
| 2022 | 0.56x | ₩29.00 Billion | ₩51.58 Billion | ▼ -3.5% |
| 2021 | 0.58x | ₩40.62 Billion | ₩69.73 Billion | ▲ +23.3% |
| 2020 | 0.47x | ₩33.63 Billion | ₩71.17 Billion | ▲ +7.3% |
| 2019 | 0.44x | ₩35.26 Billion | ₩80.08 Billion | ▼ -7.5% |
| 2018 | 0.48x | ₩44.94 Billion | ₩94.39 Billion | ▲ +59.5% |
| 2017 | 0.30x | ₩20.45 Billion | ₩68.52 Billion | ▼ -28.0% |
| 2016 | 0.41x | ₩27.92 Billion | ₩67.36 Billion | ▲ +43.0% |
| 2015 | 0.29x | ₩17.98 Billion | ₩61.99 Billion | ▲ +106.5% |
| 2014 | 0.14x | ₩9.48 Billion | ₩67.52 Billion | — |